Is Charles River Laboratories International (CRL) Fairly Valued Or Is More Upside Left?
Fresh attention on Charles River Laboratories International (CRL) follows sector data showing the global animal model market projected at US$3.6b by 2032, alongside CRL’s 48.4% year-to-date gain relative to medical peers.
In the short term, momentum has cooled, with the 7 day and 30 day share price returns both slightly negative after a strong 90 day gain of 25.8%. Charles River Laboratories International’s 1 year total shareholder return of 63.6% and 3 year total shareholder return of 50% suggest longer term buyers have still been rewarded, despite a 5 year total shareholder return that is down 29.1%.
Scan Charles River Laboratories International alongside a hand-picked group of research and healthcare service peers using the list of solid balance sheet and fundamentals (26 results) to see how its recent momentum compares.
After a sharp run and a modest recent pullback, Charles River Laboratories International now trades only slightly below the average analyst target, while intrinsic estimates sit even closer to the screen price. Where does fair value really land in that gap?
Most Popular Narrative: 5% Undervalued
Charles River Laboratories International last closed at $290.19, while the most followed narrative pegs fair value at $305.00, leaving only a narrow valuation gap that hinges on execution and capital allocation.
The company's ongoing diversification and enhancement of its capabilities through investments in new approach methodologies (NAMs), automation, and digitalization positions it to benefit from industry shifts toward more complex and high-value testing. This also mitigates risks from regulatory and client preferences away from animal testing, improving operational efficiency and supporting future margin stability.
See why 4 investors see Charles River Laboratories International as 5% undervalued.
Result: Fair Value of $305.00 (UNDERVALUED)
Still, Charles River Laboratories International faces real pressure if funding for early stage R&D stays weak or if clients accelerate a shift toward non-animal testing alternatives.
Find out about the key risks to this Charles River Laboratories International narrative.
Another View: Charles River Laboratories International Through Cash Flows
That fair value of $305.00 comes from earnings and multiples. A different lens, the Simply Wall St DCF model, puts Charles River Laboratories International’s future cash flows at about $289.31 per share, just below the $290.19 price. If cash flows sit this close to the screen price, how much margin of safety is really left?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Charles River Laboratories International for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 31 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Mixed messages on Charles River Laboratories International so far. If you want to move quickly and build your own stance, weigh the 2 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Charles River Laboratories International?
Do not stop with Charles River Laboratories International. Broaden your watchlist now, because the strongest opportunities often show up where fewer people are looking.
- Target resilient balance sheets and steady fundamentals with a curated list of solid balance sheet and fundamentals (26 results).
- Hunt for mispriced quality by scanning a focused set of 31 high quality undervalued stocks.
- Spot future market favorites early by reviewing a carefully filtered group of 19 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com